Morgan Stanley Lowers UnitedHealth Group (UNH) Price Target to $285.00

UnitedHealth Group (NYSE:UNH) had its target price cut by Morgan Stanley from $315.00 to $285.00 in a research note published on Wednesday morning, BenzingaRatingsTable reports. They currently have an overweight rating on the healthcare conglomerate’s stock.

Several other equities research analysts also recently weighed in on the company. Cleveland Research restated a buy rating on shares of UnitedHealth Group in a report on Friday, January 11th. Credit Suisse Group restated a buy rating and set a $310.00 price target on shares of UnitedHealth Group in a report on Friday, February 8th. Stephens initiated coverage on UnitedHealth Group in a report on Monday, January 14th. They set an overweight rating and a $287.00 price target on the stock. Zacks Investment Research downgraded UnitedHealth Group from a buy rating to a hold rating in a report on Tuesday, March 19th. Finally, Cantor Fitzgerald restated a buy rating and set a $310.00 price target on shares of UnitedHealth Group in a report on Tuesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. UnitedHealth Group currently has an average rating of Buy and a consensus target price of $291.56.

Shares of NYSE UNH opened at $221.75 on Wednesday. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. UnitedHealth Group has a 1-year low of $208.07 and a 1-year high of $287.94. The stock has a market cap of $212.78 billion, a price-to-earnings ratio of 16.35, a P/E/G ratio of 1.19 and a beta of 0.79.



UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Tuesday, April 16th. The healthcare conglomerate reported $3.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.60 by $0.13. UnitedHealth Group had a return on equity of 25.07% and a net margin of 5.45%. The company had revenue of $60.30 billion for the quarter, compared to the consensus estimate of $59.72 billion. During the same quarter in the prior year, the business earned $3.04 EPS. UnitedHealth Group’s revenue was up 9.2% on a year-over-year basis. On average, research analysts expect that UnitedHealth Group will post 14.7 earnings per share for the current fiscal year.

In other news, Director Richard T. Burke sold 5,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $245.01, for a total transaction of $1,225,050.00. Following the completion of the transaction, the director now directly owns 182,372 shares of the company’s stock, valued at approximately $44,682,963.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gail R. Wilensky sold 2,930 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $253.39, for a total value of $742,432.70. Following the transaction, the director now directly owns 64,726 shares of the company’s stock, valued at $16,400,921.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,930 shares of company stock valued at $4,587,133. Insiders own 0.87% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in UNH. CI Investments Inc. boosted its position in shares of UnitedHealth Group by 5.8% in the 3rd quarter. CI Investments Inc. now owns 949,719 shares of the healthcare conglomerate’s stock valued at $252,663,000 after purchasing an additional 52,023 shares during the period. Martingale Asset Management L P lifted its position in UnitedHealth Group by 1.7% during the 3rd quarter. Martingale Asset Management L P now owns 214,133 shares of the healthcare conglomerate’s stock worth $56,969,000 after acquiring an additional 3,598 shares during the period. Blue Fin Capital Inc. lifted its position in UnitedHealth Group by 7.2% during the 3rd quarter. Blue Fin Capital Inc. now owns 10,689 shares of the healthcare conglomerate’s stock worth $2,844,000 after acquiring an additional 722 shares during the period. Capital Guardian Trust Co. lifted its position in UnitedHealth Group by 0.6% during the 3rd quarter. Capital Guardian Trust Co. now owns 276,790 shares of the healthcare conglomerate’s stock worth $73,637,000 after acquiring an additional 1,571 shares during the period. Finally, Bamco Inc. NY lifted its position in UnitedHealth Group by 230.0% during the 3rd quarter. Bamco Inc. NY now owns 2,419 shares of the healthcare conglomerate’s stock worth $644,000 after acquiring an additional 1,686 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.

Recommended Story: Analyst Ratings Trading

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.